SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 187 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.83 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $62 | -99.9% | 3,688 | -10.0% | 0.00% | 0.0% |
| Q3 2022 | $70,000 | 0.0% | 4,098 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $70,000 | 0.0% | 4,098 | 0.0% | 0.00% | +100.0% |
| Q1 2022 | $70,000 | +2233.3% | 4,098 | +1889.3% | 0.00% | – |
| Q2 2021 | $3,000 | 0.0% | 206 | -17.6% | 0.00% | – |
| Q1 2021 | $3,000 | -25.0% | 250 | -7.1% | 0.00% | – |
| Q4 2020 | $4,000 | +300.0% | 269 | +31.9% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 204 | +30.8% | 0.00% | – |
| Q2 2020 | $1,000 | 0.0% | 156 | 0.0% | 0.00% | – |
| Q1 2020 | $1,000 | 0.0% | 156 | 0.0% | 0.00% | – |
| Q4 2019 | $1,000 | 0.0% | 156 | -1.9% | 0.00% | – |
| Q3 2019 | $1,000 | -87.5% | 159 | -68.2% | 0.00% | – |
| Q3 2018 | $8,000 | +300.0% | 500 | +316.7% | 0.00% | – |
| Q2 2018 | $2,000 | 0.0% | 120 | +7.1% | 0.00% | – |
| Q1 2018 | $2,000 | 0.0% | 112 | 0.0% | 0.00% | – |
| Q4 2017 | $2,000 | 0.0% | 112 | +6.7% | 0.00% | – |
| Q3 2017 | $2,000 | – | 105 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |